CytomX Therapeutics Inc. will use $70 million from a Series D financing round to deepen its own portfolio of experimental cancer drugs and set the stage for an initial public offering. The South San Francisco biotech company, which now has raised $142 million in equity funding and more than $75 million from a trio of partnership deals, said late Tuesday that its latest, oversubscribed round was led by Fidelity Management & Research Co.